#1 Clinical Trials Search in Europe

Study on Sleep and Temperature Changes in Alzheimer’s Disease for Down Syndrome Patients Using Izaflortaucipir (18F)

2 1 1

What is this study about?

This clinical trial is focused on studying the relationship between sleep disorders and changes in body temperature as potential risk factors for the progression of Alzheimer’s disease in individuals with Down syndrome. The study involves the use of a special imaging agent called [18F]PI-2620, which is a solution for injection. This agent helps in visualizing certain brain changes associated with Alzheimer’s disease.

The purpose of the study is to understand how sleep and body temperature might influence the development of Alzheimer’s disease in people with Down syndrome. Participants will receive an injection of the imaging agent [18F]PI-2620 through a slow injection into a vein. This will allow researchers to take detailed images of the brain using a technique called magnetic resonance imaging (MRI). These images will help in assessing changes in the brain over time.

The study will follow participants over a period to observe any changes in their brain structure and function. The information gathered from this study could provide valuable insights into how sleep and body temperature affect Alzheimer’s disease progression in individuals with Down syndrome. Participants will be monitored for any changes in their condition, and the results will contribute to a better understanding of these complex interactions.

1 initial assessment

Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes verifying the diagnosis of Down syndrome and ensuring there is no acquired cognitive impairment.

A series of neuropsychological evaluations will be performed to assess intellectual abilities and general health status.

2 baseline imaging

A baseline imaging session will be scheduled. This involves an MRI scan to capture detailed images of the brain structure.

The [18F]PI-2620 solution will be administered through an intravenous slow bolus injection to help visualize specific brain regions.

3 follow-up assessments

Regular follow-up assessments will be conducted to monitor changes over time. These assessments will include additional neuropsychological evaluations and imaging sessions.

The frequency and duration of these follow-up assessments will be determined by the study protocol and communicated during the trial.

4 final evaluation

At the end of the study period, a final evaluation will be conducted. This will include a comprehensive review of all collected data, including imaging and neuropsychological results.

The final evaluation aims to assess the relationship between sleep disorders, body temperature variations, and the progression of Alzheimer’s disease in individuals with Down syndrome.

Who Can Join the Study?

  • People with Down syndrome who are between 40 and 60 years old.
  • Both men and women can participate.
  • Participants should have mild to moderate intellectual disabilities, which means they may have some learning difficulties but can still understand and follow instructions.
  • A confirmed diagnosis of Down syndrome through karyotyping, which is a test that looks at the chromosomes in cells.
  • Participants should not have any additional cognitive impairments, which means no extra problems with thinking, memory, or understanding, as shown by special tests called neuropsychological evaluations.
  • Participants should be in good general health, meaning they do not have any serious illnesses or conditions that could affect their overall well-being.

Who Cannot Join the Study?

  • Patients who do not have a diagnosis of Alzheimer’s Disease cannot participate.
  • Patients who do not have Down Syndrome cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hifganaf Dh Lo Sqxci Cbgl I Sfom Phx Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Recruiting
02.10.2023

Trial locations

Investigated drugs:

I’m sorry, but the provided data does not contain any specific medications or therapies involved in the clinical trial. If you have more detailed information about the medications or therapies used in this trial, please provide it so I can assist you further.

Investigated diseases:

Alzheimer’s Disease – Alzheimer’s disease is a progressive neurological disorder that leads to the degeneration of brain cells. It primarily affects memory, thinking, and behavior. The disease typically begins with mild memory loss and confusion, which gradually worsen over time. As it progresses, individuals may experience difficulties with language, disorientation, mood swings, and impaired judgment. In advanced stages, individuals may lose the ability to carry out daily activities and recognize loved ones. The progression of Alzheimer’s disease varies among individuals, but it generally leads to significant cognitive decline.

Down Syndrome – Down syndrome is a genetic disorder caused by the presence of an extra chromosome 21. It is characterized by developmental delays and physical features such as a flat facial profile, upward slanting eyes, and a single deep crease across the palm. Individuals with Down syndrome often experience mild to moderate intellectual disability. The condition can also be associated with various health issues, including heart defects and thyroid problems. Developmental milestones, such as walking and talking, may be delayed. The progression of Down syndrome varies, with some individuals achieving a high level of independence and others requiring lifelong support.

Trial ID:
2023-506609-21-00
Protocol code:
IIBSP-DOW-2022-150
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer’s disease patients: Long-term safety evaluation

    Recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Croatia Czechia France Greece Hungary +5

  • A study testing trontinemab compared to placebo in patients with early Alzheimer’s disease including mild cognitive impairment and mild dementia

    Recruiting

    3 1 1
    Investigated drugs:
    Denmark France Germany Italy Poland Spain